Coronary Artery Disease

SAN FRANCISCO — Intravenous administration of a novel liposomal formulation of alendronate at the time of PCI with drug-eluting stents failed to reduce restenosis at 9 months in patients with diabetes enrolled in the BLADE-PCI trial.

Adults with type 2 diabetes prescribed a combination of insulin and pioglitazone therapy were 50% less likely to die during follow-up when compared with adults prescribed insulin without pioglitazone, with findings driven by a lower risk for noncardiovascular death, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

SAN FRANCISCO — Final 5-year data from the EXCEL trial demonstrate similar rates of death, stroke or MI with PCI or CABG for treatment of patients with left main CAD, according to late-breaking data presented at TCT 2019.

Adults with type 2 diabetes may be at greater risk for major adverse cardiovascular events and microvascular complications if they frequently experience changes in HbA1c of 0.5% or more, according to findings presented at the European Association for the Study of Diabetes Annual Meeting.

PARIS — Among patients with suspected acute coronary syndromes, new data from the NZOTACS trial show no difference in 30-day mortality for those treated with a high-oxygen protocol or a more conservative protocol that recommended limited oxygen.

Shockwave Medical announced that the FDA has granted a breakthrough device designation to its intravascular lithotripsy device for the treatment of complex calcified CVD.

Xarelto monotherapy was noninferior to Xarelto plus an antiplatelet agent in regards to CV events and death from any cause in patients with atrial fibrillation and stable coronary artery disease, according to open-label trial data presented at the European Society of Cardiology Congress.

PARIS — Metabolic surgery for patients with obesity and type 2 diabetes was linked to lower incidence of major adverse CV events compared with nonsurgical methods of metabolic management, according to a presentation at the European Society of Cardiology Congress.

PARIS — A 1-hour protocol including a high-sensitivity troponin T assay was associated with faster discharge of patients with suspected ACS compared with a 3-hour protocol, and it was noninferior in terms of clinical outcomes, researchers reported at the European Society of Cardiology Congress.

PARIS — Ten-year follow-up data from the SYNTAXES trial highlight no significant difference in all-cause death among patients who underwent PCI using first-generation paclitaxel-eluting stents or CABG.